AKK PROBIO Becomes First Gut-Derived Akkermansia muciniphila Strain to Clear FDA New Dietary Ingredient Review

AKK PROBIO, Maypro’s Akkermansia muciniphila ingredient developed by Thankcome Biological Science and Technology, has completed the FDA’s New Dietary Ingredient (NDI) notification process,¹ listed as Notification #1468.

According to the companies, it is the first Akkermansia muciniphila strain of human intestinal origin to clear this specific regulatory pathway, which requires documentation covering strain characterization, manufacturing controls, and toxicological assessment.

"The successful completion of the FDA NDI review represents an important milestone in the evolution of Akkermansia muciniphila from promising microbiome research to commercial reality," noted Abhijit Natu, Maypro’s vice president of US nutrition. "Supported by an expanding portfolio of human clinical studies, peer-reviewed publications, and intellectual property, AKK PROBIO is helping define a new class of clinically substantiated microbiome ingredients."

What Does an NDI Notification Actually Confirm?

An NDI notification is a premarket safety filing required for dietary ingredients not marketed in the United States before October 1994. Completing the process means the agency did not object to the safety evidence submitted, but it is not an efficacy review, and it does not evaluate or endorse specific health claims a company may make about the ingredient.

For manufacturers evaluating AKK PROBIO, the notification provides a documented safety record and regulatory precedent, distinct from, though complementary to, the ingredient's separate self-affirmed GRAS status covering both its live and pasteurized forms.

What Does Independent Research Show About Akkermansia muciniphila?

Akkermansia muciniphila has drawn substantial independent research interest over the past several years, separate from any single company's proprietary strain. An early human proof-of-concept trial, published in Nature Medicine in 2019, found that daily supplementation with a pasteurized Akkermansia muciniphila strain improved insulin sensitivity by roughly 29% and reduced circulating insulin and total cholesterol compared with placebo in a small group of overweight, insulin-resistant adults over 3 months.²

More recent controlled trials on pasteurized strains have extended into weight maintenance and muscle health: a 2026 randomized trial found that a pasteurized strain reduced weight regain during a maintenance phase following diet-induced weight loss, with the strongest cardiometabolic benefits observed in participants who started with lower baseline Akkermansia levels.³

Separately, a 12-week trial in adults over 60 found that a different pasteurized Akkermansia strain improved muscle strength measures compared with placebo.⁴ It's worth noting these trials were conducted on strains developed by other companies rather than AKK PROBIO specifically, though they establish category-level plausibility for the mechanisms Maypro is citing.

What Should Manufacturers Understand About This Ingredient Category's Evidence Base?

The pattern across independent Akkermansia muciniphila research so far shows some consistency, particularly around metabolic markers and gut barrier function, but effect sizes and outcomes have varied by trial population and strain, and at least 1 larger trial found no significant effect on whole-body insulin sensitivity in its overall study population, with benefits emerging only in a subgroup with lower baseline Akkermansia levels.⁵

That variability underscores a broader point for finished product manufacturers: research conducted on one Akkermansia muciniphila strain does not automatically transfer to another, even within the same species, and company-specific data, including AKK PROBIO's 7 cited human studies, should be evaluated on its own terms rather than assumed to inherit the wider category's research base.

References

1. Maypro. Maypro announces FDA NDI milestone for AKK PROBIO. July 16, 2026. Accessed July 17, 2026. Press release provided via email.

2. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103. doi:10.1038/s41591-019-0495-2

3. Mount S, Canfora EE, Jocken JW, et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nat Med. Published online May 2026. doi:10.1038/s41591-026-04394-7

4. Kang CH, Jung ES, Jung SJ, et al. Pasteurized Akkermansia muciniphila HB05 (HB05P) improves muscle strength and function: a 12-week, randomized, double-blind, placebo-controlled clinical trial. Nutrients. 2024;16(23):4037. doi:10.3390/nu16234037

5. Suenaert P, Segers A, Rymenans L, et al.Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut Microbes. Published online 2026. doi:10.1080/19490976.2026.2690689